Clinical trial
Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus…
NCT00054210 · CTI BioPharma, Industry · Terminated
Key facts
| NCT number | NCT00054210 |
|---|---|
| Title | Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer |
| Official title | CT-2103/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of PS = 2 Patients With Chemotherapy Naive Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase III Study |
| Lead sponsor | CTI BioPharma, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, paclitaxel, paclitaxel poliglumex |
| Start date | Jan 1, 2003 |
| Primary completion | Oct 1, 2004 |
| Completion | Oct 1, 2004 |
| First posted | Feb 6, 2003 |
| Last update posted | Oct 5, 2020 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: